Transcriptions
Note: this content has been automatically generated.
00:00:00
Posted from somebody a sense you heard
00:00:03
it at the beginning of the year in the
00:00:05
headlines there was a clinical trial in
00:00:07
France that went wrong. And that one
00:00:09
person read that and other people would
00:00:11
secure read damage. We still don't
00:00:14
really understand how how drugs affect
00:00:19
some people and not others. And there
00:00:21
is a six year gap between the cell
00:00:24
culture that we are not aware we
00:00:26
develop drugs and the patient. We need
00:00:29
to be able to understand patient
00:00:31
variation before going into patients
00:00:33
and we're trying to do this by genetic
00:00:35
profiling but genetic programming can
00:00:37
only tell us so much what it doesn't
00:00:39
tell us how the environment of of the
00:00:42
disease. And off cells affect diseases.
00:00:45
And the only way to do this is with
00:00:46
stem cell cultures stem cells like hurt
00:00:49
are the cells in our body that have all
00:00:51
the regenerative potential they can
00:00:52
make all functional cells of our body.
00:00:54
And we can harness complications and be
00:00:57
patient specific samples this is what
00:00:59
we do at some bioscience we're creating
00:01:02
patient specific meaning morgan's for
00:01:04
drug screening we're doing this large
00:01:06
scale this is a three dimensional cell
00:01:08
culture that has all the benefits of a
00:01:11
three dimensional so culture. We are
00:01:13
able to scale these cultures for for
00:01:15
drug screenings and in the future we
00:01:18
will be able to make use kind of
00:01:19
working with from every single patient
00:01:22
to patient specific medication
00:01:25
adjustment right now we're working on
00:01:28
it S not organise for cystic fibrosis
00:01:30
and retinal arguments for written